Halozyme Therapeutic (HALO) Stock Price, Quote & News

Company Profile

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subc...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 794 8889

Fax: 858 704 8311

Website: halozyme.com

Address:

12390 El Camino Real, San Diego, United States

Sean29md Dec. 5 at 11:23 AM

$HALO TD Cowen buy rating today. Target $79.https://www.moomoo.com/news/post/60817933/td-cowen-maintains-halozyme-therapeutics-halous-with-buy-rating-maintains?level=1&data_ticket=1764933553519339

0 · Reply

Sean29md Dec. 5 at 1:04 AM

$HALO … Make that 16% down for Alteogen. The South Korean investors know the significance of this win for Halozyme. Halozyme share price is dominated almost entirely by institutions and many of those are super slow to move. Once the significance of this news registers with them, they will start buying. Watch for a sustained run in halozyme share price and new all time highs is short order. Who knows maybe we will get aome retail investors in halozyme too.

1 · Reply

Sean29md Dec. 5 at 12:41 AM

$HALO ....Make that Alteogen down 11% and now trading is seemingly halted

0 · Reply

Sean29md Dec. 5 at 12:34 AM

$HALO On the news of Halozyme's win against Merck, Alteogen's stock is down 5% in South Korea in early trading. Their market opened up a few minutes ago. 196170.KQ has dropped 5.39% to ₩491,000.00. Check it out on Yahoo Finance https://finance.yahoo.com/quote/196170.KQ?p=196170.KQ

0 · Reply

BillionerOfKing Dec. 4 at 8:20 PM

$HALO Current Stock Price: $63.21 Contracts to trade: $65 HALO Dec 19 2025 Call Entry: $1.35 Exit: $2.60 ROI: 92% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Sean29md Dec. 4 at 7:57 PM

$HALO This ruling is a major pivot in Halozyme’s favor, shifting the dispute from a protracted PTAB/district court slog to a more immediate strategic win.

0 · Reply

Sean29md Dec. 4 at 7:42 PM

$HALO As I have been saying for sometime now, Merck will pay MDASE licensing fees, which means Astra Zenenca and the other company that signed with Alteogen will pay Halozyme for the MDASES licensing. Another longterm source of licensing revenue for halo for many years to come

0 · Reply

Doozio Dec. 4 at 7:19 PM

$HALO that $WLY 🐑?

0 · Reply

NoobyDoo Dec. 4 at 6:49 PM

$HALO Last chance to buy under $64… 🚀 ⬆️

0 · Reply

roadtograz Dec. 4 at 6:46 PM

$HALO Big development for Halozyme: Germany has halted Merck’s Keytruda SC launch after finding likely infringement of Halozyme’s MDASE patent. It’s an interim ruling, but the first judicial signal that MDASE is defensible and enforceable. Impact on the U.S. case? Not binding—but strategically important. It strengthens Halozyme’s narrative, increases leverage ahead of the 2026 trial, and elevates the odds of a licensing path rather than a prolonged fight. Meanwhile, Halozyme’s fundamentals remain driven by ENHANZE: royalty revenue projected to double by 2028, and EPS expanding to ~$8.25–8.85 on strong partner growth. At ~9–11x forward earnings, the stock still prices in zero litigation optionality.

0 · Reply

Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case

Dec 4, 2025, 1:26 PM EST - 22 hours ago

Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany

Dec 2, 2025, 3:43 PM EST - 2 days ago

Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript

Nov 25, 2025, 8:30 AM EST - 10 days ago

Halozyme to Participate in the 8th Annual Evercore Healthcare Conference

Nov 18, 2025, 8:50 AM EST - 17 days ago

Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery

Nov 17, 2025, 8:45 AM EST - 18 days ago

Why I Keep Buying These 10 Incredible Growth Stocks

BROS GLBE KNSL MELI RBRK RKLB SPSC

Nov 17, 2025, 7:00 AM EST - 18 days ago

Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab

MRUS

Nov 10, 2025, 1:00 PM EST - 24 days ago

The Big 3: OKLO, HALO, V

OKLO V

Nov 7, 2025, 8:30 AM EST - 4 weeks ago

FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma

Nov 6, 2025, 11:37 PM EST - 4 weeks ago

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Nov 5, 2025, 5:12 PM EST - 4 weeks ago

Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look

Nov 5, 2025, 4:05 PM EST - 4 weeks ago

Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

Nov 3, 2025, 8:16 PM EST - 4 weeks ago

Halozyme Therapeutics, Inc. (HALO) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 4:01 PM EST - 4 weeks ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

Oct 23, 2025, 1:17 PM EDT - 6 weeks ago

Halozyme Just Bought Its Next Decade Of Growth

Oct 21, 2025, 8:30 AM EDT - 6 weeks ago

Halozyme to Report Third Quarter 2025 Financial and Operating Results

Oct 10, 2025, 8:35 AM EDT - 2 months ago

Strong And Rising: Halozyme Therapeutics Stock May Have More Upside

Oct 1, 2025, 3:22 PM EDT - 2 months ago

Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript

Oct 1, 2025, 7:16 AM EDT - 2 months ago

Halozyme to buy Elektrofi for $750 million to expand drug delivery lineup

Oct 1, 2025, 7:00 AM EDT - 2 months ago

Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

Sep 8, 2025, 10:29 AM EDT - 3 months ago

Halozyme Therapeutics, Inc. (HALO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 4, 2025, 5:34 PM EDT - 3 months ago

Halozyme Therapeutics, Inc. (HALO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Prepared Remarks Transcript

Aug 29, 2025, 2:01 PM EDT - 3 months ago

Identify Superstar Stocks Like Halozyme with Money Flows

Aug 28, 2025, 8:30 AM EDT - 3 months ago

Halozyme to Participate at Upcoming Investor Conferences

Aug 6, 2025, 5:45 AM EDT - 4 months ago

Halozyme Therapeutics, Inc. (HALO) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 10:26 PM EDT - 4 months ago

Halozyme (HALO) Q2 EPS Jumps 69%

Aug 5, 2025, 4:01 PM EDT - 4 months ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS

Jul 23, 2025, 11:36 AM EDT - 4 months ago

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

Jul 22, 2025, 8:30 AM EDT - 4 months ago

Halozyme to Report Second Quarter 2025 Financial and Operating Results

Jul 14, 2025, 4:33 PM EDT - 5 months ago

Halozyme: Is Robust Growth Masking A Long-Term Value Trap? (Rating Downgrade)

Jun 30, 2025, 4:05 PM EDT - 5 months ago

Halozyme Therapeutics Added to Russell 1000® Index

Jun 20, 2025, 1:15 PM EDT - 5 months ago

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

May 28, 2025, 8:30 AM EDT - 6 months ago

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

May 12, 2025, 10:44 AM EDT - 7 months ago

Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat

May 6, 2025, 7:15 PM EDT - 7 months ago

Halozyme Therapeutics, Inc. (HALO) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:01 PM EDT - 7 months ago

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

May 5, 2025, 5:15 PM EDT - 7 months ago

Halozyme to Participate in the BofA Securities 2025 Healthcare Conference

May 1, 2025, 9:06 AM EDT - 7 months ago

Halozyme Therapeutics: Still Undervalued Ahead Of Earnings

Apr 28, 2025, 8:30 AM EDT - 7 months ago

Halozyme to Report First Quarter 2025 Financial and Operating Results

Apr 28, 2025, 7:30 AM EDT - 7 months ago

Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Apr 24, 2025, 8:30 AM EDT - 8 months ago

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

Apr 10, 2025, 6:15 PM EDT - 8 months ago

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

Apr 9, 2025, 8:45 AM EDT - 8 months ago

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

Apr 7, 2025, 9:29 AM EDT - 8 months ago

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Mar 31, 2025, 8:30 AM EDT - 8 months ago

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications

Mar 21, 2025, 7:35 AM EDT - 9 months ago

Halozyme Joins the $1 Billion Club

Feb 26, 2025, 8:30 AM EST - 10 months ago

Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference

Feb 18, 2025, 7:55 PM EST - 10 months ago

Halozyme Therapeutics, Inc. (HALO) Q4 2024 Earnings Call Transcript

Feb 18, 2025, 4:01 PM EST - 10 months ago

HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS

Feb 4, 2025, 8:30 AM EST - 10 months ago

Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results

Sean29md Dec. 5 at 11:23 AM

$HALO TD Cowen buy rating today. Target $79.https://www.moomoo.com/news/post/60817933/td-cowen-maintains-halozyme-therapeutics-halous-with-buy-rating-maintains?level=1&data_ticket=1764933553519339

0 · Reply

Sean29md Dec. 5 at 1:04 AM

1 · Reply

Sean29md Dec. 5 at 12:41 AM

$HALO ....Make that Alteogen down 11% and now trading is seemingly halted

0 · Reply

Sean29md Dec. 5 at 12:34 AM

0 · Reply

BillionerOfKing Dec. 4 at 8:20 PM

0 · Reply

Sean29md Dec. 4 at 7:57 PM

$HALO This ruling is a major pivot in Halozyme’s favor, shifting the dispute from a protracted PTAB/district court slog to a more immediate strategic win.

0 · Reply

Sean29md Dec. 4 at 7:42 PM

0 · Reply

Doozio Dec. 4 at 7:19 PM

$HALO that $WLY 🐑?

0 · Reply

NoobyDoo Dec. 4 at 6:49 PM

$HALO Last chance to buy under $64… 🚀 ⬆️

0 · Reply

roadtograz Dec. 4 at 6:46 PM

0 · Reply

NoobyDoo Dec. 4 at 6:38 PM

$HALO News v Merck lookin good for $HALO 🚀

0 · Reply

Itinerant Dec. 4 at 6:37 PM

$HALO What a coincidence!! Goldman Sachs beats down the price of the stock with a ridiculous price target, and then, miraculously, the company wins a major legal decision in Germany!! Meanwhile, the institutional clients of GS have been gobbling up the shares of the company from retail sellers for the past several days. Nothing to see hear. No insider trading here. It's amazing how lucky GS is. Disgusting.

1 · Reply

DaBullRunner Dec. 4 at 6:36 PM

🚨EPOW🚨no one seems to be talking about this…. yet……. JUST WAIT TIL THIS STARTS TO GET SOCIAL MEDIA TALKING Because $30 MILLION is a HUGE deal for this tiny company HOLDING FOR GOLD $PTEN $ANPA $HALO $ASTS $WULF let’s get it bulls

1 · Reply

davidschrier Dec. 4 at 6:35 PM

$HALO Looks like bottom is finally in, revealing that the downgrade was indeed to cause a flush. Now the covering is underway in earnest. Don't sell cheap.

0 · Reply

NoobyDoo Dec. 4 at 6:35 PM

$HALO wow! Glad I added more at the absurdly low price of $62.50 earlier today! Let’s get this going!!!$$HALO should be $75-90 realistically with all that is going on with the Co.

0 · Reply

_www_larval_com_ Dec. 4 at 6:32 PM

Dumbo reporting in! $HALO just popped 3% higher to 1% (~1Mv) a moment ago, 12/19 options, follow for more volatility.

0 · Reply

Sean29md Dec. 4 at 5:35 PM

$HALO So many near term catalysts coming up: 1) January annual earnings guidance update. Halozyme does this update every January. 2) Announcement of Enhanze partnership with Gilead (remember the leaked halo patent containing Gilead'a antibody) 3) new Enhaze deal with Regeneron/Sanofi (also a leaked Halo patent.) 4) Enhanze US patent extension to 2029. The extension was applied for a couple of years ago. Similar extension was granted by the EU authorities in 2024. 5) Merck will settle with halo and license MDASE. Halo has the upper hand with the 3 patents thay not subject to PGR's 6) Moving from a development agreement to a commercial partnership and revealing the name of the HVAI partner.

0 · Reply

davidschrier Dec. 4 at 5:23 PM

$HALO So, with their downgrade out of the way, what ammo is left for the shorts to make this go down more? Today or tomorrow latest should finally be the bottom. RSI is current 32, not gonna get much more oversold.

0 · Reply

Sean29md Dec. 4 at 5:19 PM

$HALO Halozyme CEO needs to tell the story of how HVAI and Hypercon will generate massive EPS in the 2030's to offset the nonsensical opinion and absurd downgrade by so called GS analyst. She needs to be on investment podcast, youtube channels, CNBC and bloomberg. We need a new IR director too.

1 · Reply

Doozio Dec. 4 at 2:40 PM

If the $HALO protects yo and all da 🐑 been SPOT then a Thursday 🐑 double bahhtom low on the PATH TTWO 🐒🍌🧠⏰♾️?

0 · Reply

Pittsburgh21 Dec. 4 at 2:23 PM

$HALO Close your Goldman accounts.

0 · Reply

Sean29md Dec. 4 at 2:03 PM

$HALO This is one amateurish and idiotic downgrade since just a couple of weeks ago she issued a new &quot;hold&quot; rating (first link below) with the same price target as her rating today. Ask yourself this: did anything change about halo’s future (beyond 2031) earnings during the past 2 weeks? The answer is no! Well, this is the reason she has given for this nonsensical downgrade today. These amateurish and idiotic rating from Goldman Sach’s analyst are also at odds with the Greg Tuorto, Goldman Sachs Asset Management portfolio manager, who included halozyme in his top 10 holdings when he appeared on CNBC just a couple of weeks ago. (Watch minute 6:00 on the 2rd link below) https://www.tipranks.com/news/the-fly/halozyme-price-target-raised-to-56-from-54-at-goldman-sachs-thefly https://www.cnbc.com/video/2025/11/17/goldman-sachs-greg-tuorto-environment-for-small-caps-remains-strong-despite-volatility-hits.html

1 · Reply

Market Cap	7.82B
Revenue (ttm)	1.02B
Net Income (ttm)	444.09M
EPS (ttm)	N/A
PE Ratio	12.51
Forward PE	11.15
Profit Margin	43.74%
Debt to Equity Ratio	3.00

Volume	4,213,100
Avg Vol	2,300,492
Day's Range	N/A - N/A
Shares Out	117.60M
Stochastic %K	10%
Beta	0.95
Analysts	Strong Sell
Price Target	$77.88